Smear-positive TB Cases
Conditions
Keywords
TB, cost, HEWs, Cost-effectiveness, treatment success rate
Brief summary
Evidences for policy making and decision related to the cost of delivering tuberculosis (TB) control is lacking in Ethiopia. The investigators aimed to determine the cost and cost-effectiveness of involving health extension workers (HEWs) in TB treatment under the community-based initiative in Ethiopia.
Detailed description
Two treatment options were compared - health facility and community DOT. In 1995, Ethiopia adopted World Health Organization (WHO) recommended DOTS strategy for TB control. The treatment regimen for new smear-positive patients includes two months of ethambutol, rifampicin, isoniazid and pyrazinamide followed by six months of ethambutol and isoniazid. For children the continuation phase treatment was replaced by four months of rifampicin and isoniazid. Follow up sputum examinations were conducted at the end of 2, 5 and 7 months treatment.
Interventions
OTHERTreatment
Directly observed treatment (DOT) by health extension workers (HEWs)
Sponsors
University of Bergen
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Pulmonary tuberculosis suspects of any age and sex
Exclusion criteria
* Healthy individuals or non tuberculosis patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cost per successfully treated smear-positive case | September 2006 to April 2008 |
Countries
Ethiopia
Outcome results
None listed